Taking into account about 150 million men around the globe, who suffer from impotence, the market of drugs against erectile dysfunction is perceived as a huge field of opportunities for pharmaceutical companies, promising wonders to them. However, by now this market is officially open only to the three brand-name products – Viagra, Levitra and Cialis, the manufacturers of which hold patents on their inventions.

Constantly growing number of men with ED directly affects the overall cost of treatment, which is estimated by billions of dollars today. Of course, the economic burden could be significantly decreased with the introduction of generic medications, which are usually much cheaper than brand-name pills; but the truth is that for the time being, in the countries like the USA generic drugs against impotence are not yet approved officially.

However, due to some differences in legislation and patent law in different countries, the generic alternatives of popular ED pills have already leaked into the market of ED treatments. Being supplied mostly through online pharmacies, generic versions of Viagra, Levitra or Cialis are offered at huge price discounts, which naturally attract the attention of those people, who want to improve their sexual performance and save money at the same time.

Kamagra, Silagra, Tadacip and Caverta are only several examples of cheap alternatives promoted in the internet. Such medications, being mostly produced in India, where patents on medications are not accepted, find different ways to reach their potential customers worldwide.

Pillwatch.com does not intend to focus on legal issues referring generic ED medications; our aim is to offer people some educational articles on the said products, summarizing the obvious benefits of generic drugs and revealing or pointing out some potential threats, which may be hidden, unexpressed, or passed over in silence by online sellers.